×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
OTCMKTS:TRSSF

TerrAscend Price Target, Predictions & Analyst Ratings

$2.48
+0.11 (+4.64%)
(As of 07/5/2022 03:59 PM ET)
Add
Compare
Today's Range
$2.25
$2.48
50-Day Range
$2.28
$5.35
52-Week Range
$2.25
$11.40
Volume
742,564 shs
Average Volume
241,828 shs
Market Capitalization
$457.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.73

TerrAscend (OTCMKTS:TRSSF) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 9 Analyst Ratings

Consensus Analyst Price Target

$11.08
346.77% Upside
High Prediction$17.00
Average Prediction$11.08
Low Prediction$7.90
TypeCurrent
7/5/21 to 7/5/22
1 Month Ago
6/5/21 to 6/5/22
3 Months Ago
4/6/21 to 4/6/22
1 Year Ago
7/5/20 to 7/5/21
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.08$11.08$11.08$18.54
Predicted Upside346.77% Upside56.89% Upside56.89% Upside44.18% Upside
Get TerrAscend Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TRSSF and its competitors with MarketBeat's FREE daily newsletter.


TRSSF Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TRSSF Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

TerrAscend Stock vs. The Competition

TypeTerrAscendMedical CompaniesS&P 500
Consensus Rating Score
2.89
2.72
2.51
Consensus RatingModerate BuyBuyBuy
Predicted Upside367.51% Upside458.03% Upside31.83% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
67
91.78%
Underperform Votes
6
8.22%
Avg. Outperform Votes
167
67.07%
Avg. Underperform Votes
82
32.93%
Avg. Outperform Votes
840
69.14%
Avg. Underperform Votes
375
30.86%

Historical TerrAscend Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/13/2022Echelon Wealth Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Semple
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
3/17/2022Clarus Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Atkinson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
3/17/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$8.00+61.62%
3/17/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$7.65 ➝ $7.90+59.60%
3/16/2022Atb Cap Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Tyghe
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
11/17/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuyC$23.00 ➝ C$21.00
8/20/2021Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetTop Pick ➝ Buy$21.50 ➝ $13.50+82.41%
8/20/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vivien Azer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform$13.00 ➝ $9.00+21.61%
7/7/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$17.00+53.26%
12/21/2020Beacon Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$13.50+28.57%
6/15/2020LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
(Data available from 7/5/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












TerrAscend Price Target - Frequently Asked Questions

What is TerrAscend's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for TerrAscend stock is Moderate Buy based on the current 1 hold rating and 8 buy ratings for TRSSF. The average twelve-month price prediction for TerrAscend is $11.08 with a high price target of $17.00 and a low price target of $7.90. Learn more on TRSSF's analyst rating history.

Do Wall Street analysts like TerrAscend more than its competitors?

Analysts like TerrAscend stock more than the stock of other Medical companies. The consensus rating for TerrAscend is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how TRSSF compares to other companies.

Do MarketBeat users like TerrAscend more than its competitors?

MarketBeat users like TerrAscend stock more than the stock of other Medical companies. 91.78% of MarketBeat users gave TerrAscend an outperform vote while medical companies recieve an average of 67.07% outperform votes by MarketBeat users.

Does TerrAscend's stock price have much upside?

According to analysts, TerrAscend's stock has a predicted upside of 56.89% based on their 12-month price targets.

What analysts cover TerrAscend?

TerrAscend has been rated by Echelon Wealth Partners in the past 90 days.

This page (OTCMKTS:TRSSF) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.